Blog

qordata thought leaders and subject matter experts share their insights and experiences

Ned Mumtaz
Written By
Ned Mumtaz
May 22, 2017
0 Comments

In the first week of May, qordata invited Dr. Klaus Geltsetzer to speak on how to “Determine the Relationships of Different Global Disclosure Requirements.”  He gave a comprehensive description of compliance efforts across the world, in which transparency and disclosure efforts in Germany yielded some surprising insights. Germany: Bad Boy Or Poster Child Of The Transparency Movement? As Dr. Geltsetzer stated in the webinar, the physician consent rate in Germany hovers close to 30%. In other words, only 1 in 3 physicians agrees to having his/her ToV data published. This means that of the 71,000 HCPs registered in Deutschland, the majority choose not to disclose their individual ToVs (Transfer of Value). What does that mean for transparency? In the €575m […]

Nayyara Rahman
Written By
Nayyara Rahman
May 22, 2017
0 Comments

In our previous post on Dr. Klaus Geltsetzer’s webinar presentation, how to “Determine the Relationships of Different Global Disclosure Requirements” we described how Germany’s consent rates tell an interesting story, depending on how they’re calculated. We’re resuming the debate on Germany’s position in the pharmaceutical transparency space. This time, we discuss industry-led, private sector synergy. Or lack thereof. As we learnt, thanks to Dr. Klaus Geltsetzer, there are ‘several’ Pharma associations in Europe. Prominent amongst these are: vfa (ca. 150 members) BPI (ca. 240 members) BAH (> 450 members) Pro generica (16 members) That’s an impressive number for one country. It also shows a determined, national effort towards improving pharmaceutical disclosure. Or does it? As Dr. Geltsetzer mentioned, there are over 300 […]

Nayyara Rahman
Written By
Nayyara Rahman
May 19, 2017
0 Comments

Synergy between pharma associations may never materialize. It may even backfire. We will be elaborating on this in an upcoming post, with the real-life case of pharma disclosure in Germany. Today we discuss how public interest has surfaced as a surprisingly powerful ally in the pharma transparency movement.  Before exploring the ‘whats’ and ‘hows’, we would like to talk a little about why ordinary citizens would take interest in something like pharmaceutical spend. Public Interest An obvious answer, public interest. Citizens have a right to know the composition of public and private healthcare. They need to know the components of decisions related to treatment options available to them. In this, the importance of physician-pharma relationships can be illustrated by this […]

Ned Mumtaz
Written By
Ned Mumtaz
May 15, 2017
0 Comments

At the 14th PCC, which took place in Washington DC, last month, I had the opportunity to reiterate a priority for compliance professionals. It is a priority that needs to be better understood and better implemented. Key Compliance Indicators (KCIs) are internal tools that prepare compliance/transparency professionals for better performance and reporting. What You Need To create KCIs for your company you need: Central data repositories with your company’s spend data—the more comprehensive, the better. Commercial data stores Getting Started Study both datasets (a) and (b), and create alerts based on patterns that emerge from each. Consult business lines in the establishment of the indicator, by getting realistic feedback on thresholds, limits and reporting timelines. The choice of what to […]

Upcoming Event

OOPS! NO UPCOMING EVENT

Ask an Expert

Get all the insights, and the answers to the most critical issues in pharma compliance from thought leaders in qorcommunity

ASK AWAY
OUR SOLUTIONS CAN SIMPLIFY YOUR COMPLIANCE EFFORTS.